Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
April W ArmstrongSang Hee ParkVardhaman PatelPierre NicolasWei-Jhih WangMatthew J ColomboViktor ChirikovPublished in: Dermatology and therapy (2024)
Results from this analysis corroborate the primary efficacy analysis supporting the use of deucravacitinib compared with apremilast for moderate to severe plaque psoriasis, regardless of prior systemic or biologic use.